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Background: Recent studies in animal models have shown that statins can protect against renal failure
independent of their lipid-lowering actions, and there is also an association between statin use and improved renal
function after suprarenal aortic clamping. We investigated the hypothesis that post-ischemic acute renal failure
could be ameliorated with atorvastatin (ATO) treatment and the possible molecular mechanisms in a model of
ischemia–reperfusion (IR) in rats.
Methods: Twenty-four male Sprague–Dawley rats were divided into three groups: sham, IR, and IR + ATO. ATO was
given by a single intraperitoneal injection (10 mg/kg) 30 min before reperfusion in the IR + ATO group. The IR
group and sham group received saline vehicle via the intraperitoneal route.
Results: After 24 h of IR, serum creatinine levels were increased in the IR group compared with the sham group
(p < 0.001). ATO treatment reduced the elevation of serum creatinine level by 18% (p < 0.05) and significantly
increased the creatinine clearance rate (p < 0.001). Concentrations of advanced oxidation protein products and
malondialdehyde were reduced in the ATO group, approaching levels observed in sham-group rats. ATO treatment
alleviated pathological changes in renal tubular cells. Protein and mRNA levels of intercellular adhesion molecule-1
and monocyte chemotactic protein-1 were reduced significantly.
Conclusions: These data suggest that direct protection of injured kidneys by ATO was possible even though the
drug was injected 30 min before reperfusion, and that ATO may reduce IR injury by anti-inflammatory effects and
by reducing oxidation stress.Background
The major causes of acute renal failure (ARF) are acute
renal ischemia–reperfusion injury due to hemorrhage,
severe injury, shock, or kidney transplantation. The mor-
tality associated with ARF in critically ill patients re-
mains high even though application of intensive care
and blood purification has provided advanced treatment
and a better prognosis for ARF patients [1,2]. Various
agents, including dopamine, atrial natriuretic peptide,
insulin-like growth factor, and endothelial receptor an-
tagonists have been found to be effective in animals but
ineffective in clinical studies [3-6]. It is necessary to* Correspondence: lihy0726@126.com
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reproduction in any medium, provided the orexplore and find more efficient and practical methods
for timely prevention and cure.
ARF is a complex disorder resulting from hetero-
geneous pathogenic factors. Recent studies have shown
that reactive oxygen species (ROS), inflammatory media-
tors such as intracellular adhesion molecule (ICAM-1)
and monocyte chemotactic protein-1 (MCP-1) [7,8] as
well as infiltration of inflammatory cells are implica-
ted in renal ischemia–reperfusion injury [2]. In several
studies, the effects of statins in ischemia–reperfusion
models of renal protection have been related to their anti-
inflammatory, antioxidant, and vascular actions [9-11]. Al-
though these findings suggest an association between
statin use and preserved renal function in ARF sce-
narios such as suprarenal aortic clamping, kidney trans-
plantation, and critically ill patients in the intensive care
unit [12,13], they carry little significance in patients with. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Ccr = urinary creatinine (μmol/L)
× urinary volume (mL/kg/min)/Scr (μmol/L).
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or shock. In these studies, statin intervention has been
several days before ischemia–reperfusion injury. How-
ever, the effects of statin intervention after ischemia-
reperfusion injury are not fully understood and it is of
significance to the clinical treatment of ARF. Todorovic
et al. reported that a single intravenous bolus injection of
simvastatin after ischemia could relieve tubular necrosis,
suggesting that intervention after ARF maybe improve the
prognosis [14]. Therefore, the present study was under-
taken to examine the effects and mechanisms of atorva-
statin (ATO) after renal ischemia–reperfusion injury with
focuses on tubular damage, necrosis, inflammation and
oxidant stress in rats.
Methods
All animal procedures were approved by the Animal
Experiment Committee of Southern Medical University
(Guangzhou City, China).
Animals
Male Sprague–Dawley rats (initial weight, 200–250 g;
Southern Medical University Animal Experiment Center,
Guangzhou City, China) were maintained under stan-
dardized conditions and fed a standard rodent diet, with
free access to tap water.
Model of ischemia–reperfusion injury
Surgery was undertaken with general anesthesia with 3%
napental (30 mg/kg body weight (BW); Southern Medical
University Reagent Center). Surgery was performed as de-
scribed previously [15]. Bilateral flank incisions were made
and the left renal pedicle occluded for 60 min, during
which time a right nephrectomy was carried out.
The treatment group, i.e., the ischemia–reperfusion +
atorvastatin (IR + ATO) group of rats, was given single-
dose intraperitoneal ATO (10 mg/kg BW) 30 min before
reperfusion. The control group (IR group) received sa-
line vehicle via the intraperitoneal route and underwent
a clipping procedure and contralateral nephrectomy as
described above. The third group received saline treat-
ment and underwent a sham operation (sham group).
That is, bilateral flank incisions were made, the left renal
pedicle dissected (but not clamped), and the right kidney
removed. Afterwards, the incisions were closed and ani-
mals was allowed to recover.
Samples
All animals were anesthetized for 60 min and killed 24 h
later. Each group contained eight rats. Blood samples
were obtained before surgery and at the time of killing.
Urine samples were obtained from metabolism cages 24 h
after surgery. Rats were perfused, via the aorta, with100 mL of cold phosphate-buffered saline, and their
kidneys removed.
Measurement of serum levels of creatinine (Scr) and the
creatinine clearance rate (Ccr)
Scr levels were measured and the Ccr calculated using
a Toshiba Automatic Biochemistry Analyzer (Toshiba,
Tokyo, Japan). Ccr was calculated on the basis of urinary
creatinine, serum creatinine, urine volume, and body
weight using the following formula [16]:Morphological examination
Tissue for light microscopy was fixed in 10% phosphate-
buffered formalin and embedded in paraffin. Five-
micrometer-thick sections were processed for staining
using periodic acid-Schiff and hematoxylin and eosin
(H&E). Morphological analyses were undertaken by an ex-
perienced pathologist blinded to the tissue source. The
following parameters were chosen to indicate morpho-
logical damage to the kidney after ischemia–reperfusion:
loss of brush border; formation of tubular casts; tubular
dilatation. These parameters were evaluated on a scale of
0–4: not present (0); mild (1); moderate (2); severe (3);
very severe (4). Tubular necrosis was graded from none
(0) to confluent (4). The extent of cortical necrosis was
graded from 0 to 3: no necrosis (0); necrosis confined to
the inner third of the cortex (primarily in the S3 segment
of the proximal tubules) (1); necrosis extending into the
upper third of the cortex (2); extensive necrosis of all areas
of the cortex and in which necrotic tubules are present
near the kidney surface (3). Each parameter was deter-
mined on six or more rats.
Measurement of advanced oxidation protein products
(AOPPs)
Plasma levels of AOPP were determined as described
previously [17]. To exclude the interference of the tur-
bidity of lipids upon light absorption, samples were di-
luted 1:5 in PBS and centrifuged (10,000 × g, 1 h, 4°C).
Samples below the lipid layer were used for AOPP
measurement.
Measurement of malondialdehyde (MDA) levels
The MDA level in the serum was detected using a
method described previously [18] and spectrophoto-
metry (UV–Vis Spectrometer 6105; Jenway, Stone, UK).
About 2.5 mL of trichloroacetic acid was added to 0.5
mL plasma and the tube left to stand for 10 min at room
temperature. After centrifugation at 3500 rpm for 10
min, the supernatant was decanted and the precipitate
washed with sulfuric acid. Then, 2.5 mL sulfuric acid
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were added to this precipitate. The coupling of lipid per-
oxide with TBA was carried out by heating in a boiling
water-bath for 30 min. After cooling in cold water, the
resulting chromogen was extracted with 4 mL of n-butyl
alcohol by vigorous shaking. Separation of the organic
phase was facilitated by centrifugation at 3000 rpm for
10 min and its absorbance at 530 nm determined.
Immunohistochemical analyses
Expression of ICAM-1 and MCP-1 was assessed by im-
munohistochemical analyses as described previously
[19]. Sections (thickness, 4 mm) were cut from paraffin
blocks, mounted on polylysine-coated slides, and stained
(H&E) for light microscopy. Sections were also dewaxed
in xylene, rehydrated in a descending series of alcohols,
and blocked for endogenous peroxidase and avidin/bio-
tin activities. After blocking with 3% bovine serum albu-
min (BSA) in phosphate-buffered saline (PBS), sections
were incubated with a rabbit polyclonal anti-mouse anti-
body against ICAM-1 and MCP-1 (1:150 dilution; Santa
Cruz Biotechnology, Santa Cruz, CA, USA) overnight at
4°C. Sections were then washed and incubated with a
secondary antibody (goat anti-rabbit) using the Evision +
Labeled Polymer kit (Dako, Glostrup, Denmark) for 30
min followed by incubation with avidin-biotin–peroxidase
complex (Dako) and development with diaminobenzidine
chromogen for 5 min. Finally, sections were rinsed in dis-
tilled water, counterstained with hematoxylin (Dako), and
mounted on glass slides before evaluation under the mi-
croscope. Semi-quantitative analyses of immunohisto-
chemistry were undertaken by image analysis software
(Image Pro Plus; Media Cybernetics, Rockville, MD,
USA).
Reverse transcriptase-polymerase chain reaction (RT-PCR)
Detection of ICAM-1 and MCP-1 mRNA in renal tissue
was undertaken. Briefly, total RNA of the renal tissue
samples was extracted with an RNA Extraction Agent
(TaKaRa Bio, Shiga, Japan) following manufacturer in-
structions. cDNA was synthesized using a TaKaRa Bio
Reverse Transcription kit following manufacturer in-
structions. RT-PCR was performed using the SYBR
Green kit of the TaKaRa Bio Reaction System according
to the manufacturer’s instructions. The primers for
ICAM-1 were: sense, 5′-GCGACCACGGAGCCAATT
TCTCAT-3′; anti-sense, 5′-TCAGGACCCTAGTCG-
GAAGATCGAA-3′. The primers for MCP-1 were:
sense, 5′-ACGCTTCTGGGCCTGTTGTTCA-3′; anti-
sense,5′-TGGGGCATTAACTGCATCTGGCT-3′; gly-
ceraldehyde 3-phosphate dehydrogenase was used as
the internal control. The result (Ct) from ABI7500 Fast
system was analyzed and compared using the 2-△△Ct
method.Statistical analyses
One-way analysis of variance (ANOVA) was used to
compare the different mean values in the three experi-
mental groups. The least-square difference or Dunnett’s
T3 test (equal variance not assumed) was used to ascer-
tain significant differences among the groups. Scr was
analyzed by repeated-measures ANOVA followed by
Dunnett’s T3 multiple comparison test. Histological
evaluation was assessed by the Kruskall–Wallis test
followed by the Rank sum test for multiple compari-
son. p < 0.05 was considered significant. Data are the
mean ± SD. SPSS version 13.0 (SPSS, Chicago, IL, USA)
was used for all analyses.
Results
Scr levels were decreased and Ccr levels increased in the
IR + ATO group
Sixty minutes of ischemia and subsequent reperfusion
caused a decline in renal function, and Scr levels were in-
creased significantly, compared with the sham-operated
group (270.75 ± 46.84 μmol/L vs 61.23 ± 8.49 μmol/L; p <
0.001) (Figure 1). Decreases in renal function were amelio-
rated by ATO treatment, which demonstrated increases in
Scr levels 24 h after surgery (189.00 ± 31.85 μmol/L),
compared with sham-operated animals (p < 0.05). Right
nephrectomy alone (sham operation) did not increase cre-
atinine levels.
To substantiate the effects of ATO treatment on renal
function after ischemia, we analyzed the Ccr (Figure 2).
The Ccr in sham-operated animals was 0.127 ± 0.034
mL/min and reduced to 0.015 ± 0.004 mL/min after is-
chemia–reperfusion injury. ATO significantly amelio-
rated these decreases (0.031 ± 0.006 mL/min; p < 0.001).
Pathological changes in renal tubular cells were alleviated
in IR + ATO groups
The morphological changes in tissues during different
experiments are shown in Table 1. Representative exa-
mples of these experiments are presented in Figure 3.
Ischemia–reperfusion injury caused severe damage to
epithelial cells of the proximal tubule in the renal cortex.
Loss of the brush border and detachment of epithelial
cells from the basement membrane caused tubular ob-
struction, tubular casts, and necrosis (Figure 3B). After
ATO treatment, tubular necrosis was markedly reduced
and the pathological changes described above mitigated
(Figure 3C). Kidneys from sham-operated rats are shown
in Figure 3A.
Expression of AOPP and MDA were down-regulated in
IR + ATO groups
AOPP concentrations in the IR group (74.13 ± 16.81
μmol/L) differed significantly (p < 0.001) from those in
the sham group (43.25 ± 5.10 μmol/L) and the ATO
n=8
Figure 1 Scr before (shaded square symbol) and 24 h after (□) ischemia–reperfusion injury. Ischemia–reperfusion injury and treatment
with saline vehicle resulted in significant elevation of the Scr level after 24 h. Treatment with ATO after ischemia–reperfusion injury (IR + ATO)
reduced the impairment of kidney function compared with the IR group (one-way ANOVA test; p < 0.05; n = 8). A right nephrectomy without
ischemia of the contralateral kidney (sham) did not increase the Scr level after 24 h.
n=8
Figure 2 Ccr after 60 min of ischemia without treatment (IR) or with ATO pretreatment (IR + ATO), compared with sham-operated
control animals (sham). IR induced decreases in the Ccr (one-way ANOVA test; *p < 0.001, compared with the sham group; n = 8). Treatment
with ATO increased the Ccr (one-way ANOVA test; **p < 0.001, compared with the IR group; n = 8).
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Table 1 Quantitative evaluation of morphological kidney damage
Group N Brush border loss Tubule dilatation Casts Necrosis Extent of necrosis
Sham 6 3.75a 3.92a 3.83a 3.67a 4.25a
IR 6 15.33a 15.33a 15.00a 15.42a 14.50a
IR + ATO 6 9.42a 9.25a 9.67a 9.42a 9.75a
Histologic evaluation of kidney after renal ischemia.
Morphology was scored according to loss of brush borders of proximal tubules, cast formation within tubules, tubule dilatation, and tubule necrosis.
Kruskall–Wallis test. Values represent mean rank. ap < 0.05; n = 6. There is a significant difference between the three groups and according to the rank sum test,
and multiple comparison test (values represent the mean, subset for alpha = 0.05).
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cantly decreased in the ATO group compared with the
IR group (p < 0.005) (Figure 4A). Serum levels of MDA
in the IR group (13.86 ± 0.99 nmol/L) differed signifi-
cantly from those in the sham group (9.57 ± 1.41 nmol/L)
and the ATO group (12.04 ± 1.97 nmol/L). They were de-
creased significantly in the ATO group compared with the
IR group (p < 0.05) (Figure 4B).Protein and mRNA levels of ICAM-1 and MCP-1 were
reduced in IR + ATO groups
We addressed the effects of ATO on expression of
ICAM-1 and MCP-1. Post-ischemic changes were re-
flected by the upregulation of adhesion molecules. Repre-
sentative immunohistologic-stained specimens are shown
in Figure 5.Figure 3 Morphological damage in the renal cortex of proximal tubu
brush border, tubular dilatation, detachment of epithelial cells from the bas
(IR + ATO) markedly reduced the pathological changes noted above. (C) Co
exhibited almost no abnormalities in the contralateral kidney. (A) H&E. MagIschemia–reperfusion injury induced massive upregula-
tion of expression of ICAM-1 and MCP-1 in renal tubules
and the cortical peritubular interstitium (Figures 5B and
E). ATO blocked ICAM-1 upregulation in the renal tubule
and cortical peritubular interstitium (Figure 5C), as well
as perivascular and endothelial upregulation of MCP-1 ex-
pression (Figure 5F). Expression of ICAM-1 and MCP-1
in control sections from the corresponding areas in the
kidneys of sham-operated rats is shown in Figures 5A and
D. Ischemia–reperfusion injury caused significant eleva-
tion of expression of ICAM-1 and MCP-1, and ATO de-
creased the upregulation of the expression of ICAM-1 and
MCP-1 in the IR group (p < 0.05) (Figure 5).
Next, we examined the mRNA changes of ICAM-1
and MCP-1 in the kidneys of rats from each group.
Ischemia–reperfusion injury caused significant elevation
of expression of ICAM-1 and MCP-1 (Figure 6). ATOles. Ischemia–reperfusion caused severe damage, with loss of the
ement membrane, and necrosis of tubular casts. (B) ATO treatment
ntrol animals after right nephrectomy without ischemia (sham)
nification, ×40 in A–C.
n=8
n=8
Figure 4 AOPP and MDA levels in different groups. A Ischemia–reperfusion induced increases in AOPP levels (one-way ANOVA test;
*p < 0.001, compared with the sham group; n = 8). Treatment with ATO significantly decreased AOPP levels (**p < 0.005; compared with the IR
group; n = 8). B MDA levels after ischemia–reperfusion were increased (one-way ANOVA test; *p < 0.001, compared with the sham group; n = 8)
and were decreased after administration of ATO (**p < 0.05, compared with the ischemia–reperfusion group; n = 8).
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and MCP-1 mRNA in the IR group. The kidneys of the
sham-operation group showed extremely low expression
of these molecules.
Discussion
The present study demonstrated that, according to the
selected biochemical and histological parameters of renal
dysfunction, ATO treatment 30 min after ischemia miti-
gated the course of ischemic ARF in rats. This observationwas supported by several key findings. ATO treatment 30
min after ischemia significantly ameliorated post-ischemic
acute tubular necrosis and considerably limited the struc-
tural damage after ischemia. Histologically, ATO treat-
ment reduced the damage to proximal tubules in the renal
cortex. Untreated animals demonstrated typical changes:
loss of the brush border, destruction of epithelial cells,
“naked” basement membranes, and tubular obstruction.
The major changes in tubules (loss of nuclei and ap-
pearance of tubular debris and casts) were remarkable.
n=8
n=8
Figure 5 Representative immunohistochemical staining profiles of expression of ICAM-1 and MCP-1 at 24 h and the results of
semi-quantitative analyses. Ischemia–reperfusion (A and D) caused significant expression of ICAM-1 and MCP-1 in renal tubules and the cortical
peritubular interstitium (B and E). Atorvastatin (IR + ATO) reduced this expression (C and F). Magnification, ×400 in A–F. Expression of ICAM-1
and MCP-1 after ischemia–reperfusion was increased (one-way ANOVA test; *p < 0.05, compared with the sham group; n = 8) and decreased after
administration of ATO (**p < 0.05, compared with the IR group; n = 8).
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creatinine and increased the Ccr, which are indicators of
impaired glomerular function. As mentioned above, des-
pite intervention being after ischemic injury, ARF could
be ameliorated with statin treatment.
There are several possible mechanisms for the protect-
ive effects of ATO. Recent studies have shown that ROS,
certain inflammatory mediators (e.g., ICAM-1, MCP-1
[7,8]), and infiltration of inflammatory cells are related
to renal ischemia–reperfusion injury [9]. During ische-
mia–reperfusion injury, reperfused tissues generate a
great deal of ROS through activation of xanthine oxidase
and NADPH oxidase. ROS not only elicit injury to re-
perfused tissue directly, they also amplify the effect of
injury of ROS through peroxidation (oxidative stress).
This view is consistent with the notion that oxidative
stress increases in critically ill patients with acute kidney
injury (AKI) [20].
AOPPs are derived from oxidation-modified albumin
(its aggregates or fragments), and are recognized as
markers of oxidative damage to proteins, the intensity ofoxidative stress, and inflammation [21]. Accumulation of
AOPPs is probably via a redox-sensitive inflammatory
pathway that causes deterioration in renal dysfunction
[22] and it is also a prognostic biomarker for recovery
from AKI after coronary artery bypass grafting [23]. Fur-
thermore, ROS also cause renal-cell injury by lipid peroxi-
dation, which results in increased membrane permeability
in cells, mitochondria, and lysosomes. MDA is one of sev-
eral low-molecular-weight end products formed via the
decomposition of certain primary and secondary lipid per-
oxidation products [24]. MDA is a reliable estimator of
lipid peroxidation [25].
We found that ischemia–reperfusion injury led to an in-
crease in levels of AOPP and MDA that were decreased
by ATO treatment. These results suggest that the protec-
tion afforded by ATO may be mediated by reducing oxida-
tive stress, particularly by decreasing the production of
oxygen free radicals and lipid peroxidation in cells.
Inflammation is another important factor causing
ischemia–reperfusion renal damage. Infiltration of in-
flammatory cells in ischemia–reperfusion injury is
n=8
n=8
Figure 6 Quantitative RT-PCR analyses of ICAM-1 mRNA and MCP-1 mRNA gene expression in kidneys. Ischemia–reperfusion caused
severe increase in expression of ICAM-1 and MCP-1 mRNAs (one-way ANOVA test; *p < 0.001 compared with the sham group; n = 8). ATO reduced
this upregulation (**p < 0.001, compared with the IR group; n = 8).
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sion of adhesion molecules [7,8]. Upregulation of ex-
pression of ICAM-1 and MCP-1 in glomeruli, renal
tubules, and the peritubular interstitium was also pre-
vented by ATO treatment. Our results showed that even
administration of ATO after ischemic ARF elicited anti-
inflammatory actions.
The most prominent injury to renal proximal tubular
cells is likely to occur during the first 2–4 h of the re-
perfusion period. Sixty minutes of ischemia does not
increase MDA levels, whereas 15 min of reperfusion re-
sults in a large increase in kidney lipid peroxidation andaggravates cell injury [14,15]. Hence, ATO administra-
tion 30 min before reperfusion can protect the kidney.
In other studies, statin intervention has been several
days before ischemia–reperfusion injury [26,27] but, in
the present study, drug intervention was after renal is-
chemia. AKI is an unpredictable event, so the present
study has more clinical relevance compared with previ-
ous studies. Haylor et al. reported that even if ATO was
administered after clamping the renal hilus but before
kidney reperfusion, renal ischemia–reperfusion injury
can be improved because of direct inhibition of activated
caspase-3 in rats [28]. Our results are consistent with
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treatment after renal ischemia also had anti-inflammatory
and anti-oxidative stress effects. In their study, ATO did
not change Scr levels but in the present study Scr levels
were decreased and Ccr levels increased in ATO groups.
This finding may be because we determined Scr levels 24
h after reperfusion, whereas in their study it was at 4 h.
Scr levels and the Ccr are the most important indices of
renal function. Taken together, the renal protection affor-
ded by ATO is not obvious 4 h after reperfusion but its ef-
fects continue for ≥4 h. The present study showed that
renal function could obviously recover in 24 h even if
ATO was given after ischemia.
Conclusions
We demonstrated that ATO given after renal ischemia
has anti-inflammatory and anti-oxidative stress effects.
Treatment of ATO ameliorated renal ischemia–reperfu-
sion injury in vivo. Levels of Scr, AOPP, MDA, ICAM-1,
and MCP-1 were reduced but the Ccr increased. Our
results suggest that acute administration of ATO after
ARF can reduce renal damage and promote recovery
of kidney function.
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